Table 2.
Percentage of 3-year coverage among patients already on treatment with specific drugs* from each category, in the presence of combined therapy with other drug categories (single category coverage). The global coverage in the presence of multiple treatments is also reported
| Covered patients | ||||
|---|---|---|---|---|
| n | % | OR | (95% CI) | |
| Single category coverage | ||||
| Antihypertensive agents | ||||
| Alone | 10 859/23 988 | 45 | Ref | |
| With LLDs | 1211/2086 | 58 | 1.67 | 1.53, 1.83 |
| With OHAs | 677/1103 | 61 | 1.92 | 1.69, 2.18 |
| With LLDs and OHAs | 93/139 | 67 | 2.44 | 1.69, 3.54 |
| Lipid-lowering agents | ||||
| Alone | 603/2946 | 20 | Ref | |
| With AHAs | 520/2086 | 25 | 1.29 | 1.13, 1.48 |
| With OHAs | 20/93 | 22 | 1.06 | 0.62, 1.80 |
| With AHAs and OHAs | 34/139 | 24 | 1.26 | 0.83, 1.90 |
| Oral hypoglycaemic agents | ||||
| Alone | 803/1297 | 62 | Ref | |
| With AHAs | 716/1103 | 65 | 1.14 | 0.96, 1.35 |
| With LLDs | 74/93 | 80 | 2.40 | 1.39, 4.16 |
| With AHAs and LLDs | 99/139 | 71 | 1.52 | 1.02, 2.28 |
| Global coverage | ||||
| AHAs + LLDs | 385/2086 | 18 | Ref | |
| AHAs + OHAs | 549/1103 | 50 | 4.38 | 3.71, 5.16 |
| OHAs + LLDs | 42/93 | 45 | 3.64 | 2.33, 5.67 |
| AHAs + LLDs + OHAs | 20/139 | 14 | 0.74 | 0.44, 1.23 |
*
Only drug categories aimed at reducing ‘global’ cardiovascular risk are considered. LLDs, Lipid lowering agents; OHAs, oral hypoglycaemic agents; AHAs, antihypertensive agents.